Brainstem stroke in a Nigerian male with prosthetic heart valves—A case report

2022 ◽  
Vol 27 (1) ◽  
pp. 104
Author(s):  
RalphC Anakwue ◽  
IkennaO Onwuekwe ◽  
RhodaC Nwutobo ◽  
ChinwenduJ Onwuekwe
2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Shirin Haghighat ◽  
Alireza Rezvani ◽  
Maral Mokhtari

Abstract Background Although life-threatening hemorrhage is a usual manifestation of acute promyelocytic leukemia (APL), thrombotic events seem to be more common in APL compared to other subtypes of acute leukemia. The treatment and prophylaxis of thrombosis are controversial due to the high risk of bleeding caused by disseminated intravascular coagulation (DIC) and thrombocytopenia. To the best of our knowledge we report the first case of APL in a patient with prosthetic heart valves successfully treated with a combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO). We hope this case report helps clinicians to manage different spectra of coagulopathy in APL successfully. Case presentation A 38-year-old Asian man presented with diagnosis of APL confirmed by bone marrow biopsy. He was on warfarin due to prosthetic mitral and aortic valves. He was at risk of both hemorrhagic events due to DIC and life-threatening valve thrombosis. Our management regimen included unfractionated heparin adjusted according to the platelet count to prevent both valve thrombosis and bleeding events. The patient tolerated treatment well without any hemorrhagic or thrombotic events, and complete molecular remission was achieved by ATRA and ATO without the need for chemotherapeutic agents. Conclusion Although this case is exceptional, a precise evaluation may be needed to select the appropriate dose and type of anticoagulant to treat a patient with APL.


2014 ◽  
Vol 47 (6) ◽  
pp. 381-385
Author(s):  
Hidenori Matsuhashi ◽  
Tomotoshi Wakasa ◽  
Takako Takita ◽  
Mitsuyoshi Furuhashi

2021 ◽  
Vol 5 (7) ◽  
Author(s):  
Alexander Marschall ◽  
Diego Rodriguez Torres ◽  
Andrea Rueda Liñares ◽  
David Martí Sánchez

Abstract Background Antithrombotic management in patients with atrial fibrillation (AF) that have undergone heart valve surgery may be challenging, especially in the context of thromboembolic events during follow-up. The combination of pharmacological therapies with modern transcatheter interventions allows these more complex cases to be overcome. Case summary We present the case of a 66-year-old female with a history of AF and mechanical aortic and mitral valve replacement, which was admitted to the hospital complaining of dizziness and unsteady gait. A computerized tomography scan of the brain confirmed the diagnosis of embolic stroke. Two years later, the patient complained of sudden onset of chest pain, accompanied by electrocardiographic abnormalities and elevated high-sensitivity troponin T. Emergency cardiac catheterization revealed embolic myocardial infarction with distal occlusion of the obtuse marginal artery. Again, 2 years later, the patient suffered a new cerebral embolic event. Given the adequate anticoagulation therapy throughout almost the entire clinical course, percutaneous left atrial appendage closure was proposed as an adjunct to vitamin K antagonist treatment. Notably, intraprocedural transoesophageal echocardiography revealed the presence of a previously undetected left atrial appendage thrombus, thus an embolic protection device was used during the procedure, which was successfully carried out without complications. Discussion This case report demonstrates the complexity of the antithrombotic management in patients with AF and prosthetic heart valves, and highlights the importance of an individualized approach, integrating new therapeutic strategies to achieve success, in patients that present thromboembolic events despite adequate anticoagulation therapy.


1973 ◽  
Vol 29 (03) ◽  
pp. 694-700 ◽  
Author(s):  
Paul L. Rifkin ◽  
Marjorie B. Zucker

SummaryDipyridamole (Persantin) is reported to prolong platelet survival and inhibit embolism in patients with prosthetic heart valves, but its mechanism of action is unknown. Fifty jxM dipyridamole failed to reduce the high percentage of platelets retained when heparinized human blood was passed through a glass bead column, but prolonged the inhibition of retention caused by disturbing blood in vitro. Possibly the prostheses act like disturbance. Although RA 233 was as effective as dipyridamole in inhibiting the return of retention, it was less effective in preventing the uptake of adenosine into erythrocytes, and more active in inhibiting ADP-induced aggregation and release. Thus there is no simple relation between these drug effects.


Circulation ◽  
1968 ◽  
Vol 37 (4s2) ◽  
Author(s):  
ROBERT A. INDEGLIA ◽  
MICHAEL A. SHEA ◽  
RICHARD L. VARCO ◽  
EUGENE F. BERNSTEIN

Circulation ◽  
1973 ◽  
Vol 48 (1s3) ◽  
Author(s):  
MICHAEL L. SCHWARTZ ◽  
DEAN SHELDON ◽  
FRANK DORMAN ◽  
PERRY L. BLACKSHEAR ◽  
RICHARD L. VARCO ◽  
...  

2019 ◽  
Vol 25 ◽  
pp. 100421
Author(s):  
Noel Alberto Flórez ◽  
German Camilo Giraldo ◽  
Julian David Yara ◽  
Stephania Galindo-Coral ◽  
Juan David López ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document